Whitfield Assists Impact Therapeutics on its Hong Kong IPO
Overview
Impact Therapeutics listed in Hong Kong on May 13, 2026, under code 7630, with reported proceeds near HK$844 million before additional allotments.
Offering terms
The biotech company offered 41,977,000 H-shares at HK$20.10 each. The source describes strong demand in both the retail and institutional tranches.
Sponsor representation
Goldman Sachs Asia and CICC Hong Kong Securities were identified as joint sponsors, the parties represented in the announcement.
Scientific focus
Impact develops cancer treatments based on synthetic lethality. Mengyu Lu, George Zheng and Qingyu Wu are among the capital markets advisers credited for the flotation.
